U.S. Expanded Access policy

Merz Therapeutics recognizes that patients may seek access to investigational uses of therapies before they are approved by regulatory authorities.

At this time, Merz Therapeutics does not offer an Expanded Access (also known as “compassionate use”) program in the United States.

As part of our development approach, Merz Therapeutics is focused on conducting clinical trials to evaluate the safety and efficacy of investigational uses of its products and to support regulatory approvals. Participation in a clinical trial is currently the only way for patients to access investigational uses of our therapies in the United States. A list of active clinical trials can be found by visiting www.clinicaltrials.gov.

Patients with questions should speak with their physician, who may contact Merz Therapeutics Medical Affairs at medinfo-txus@merz.com.

Merz Therapeutics may update this Expanded Access policy at any time. Any changes will be reflected on this page.

Platform change – You are leaving this page.

You are leaving this website. With respect to the content of the following page, as well as to links to other websites located on this page, Merz Therapeutics U.S. has no way of controlling the content of these sites. Merz Therapeutics U.S. assumes no responsibility for the content of these sites or the consequences of their use by visitors. However, we ask you to notify us immediately of any illegal content on the linked sites.

Change of country – You are leaving this page.

You are leaving this website. The content of the following sites maintained by the parent company or another affiliated company, or links to other sites located on this site, is subject to the legal requirements of the country in which the site is maintained. Merz Therapeutics U.S. accepts no responsibility whatsoever for the content of these websites or for the consequences of their use by visitors. However, we ask you to notify us immediately of any illegal content on the linked sites.